Driving Biosimilar Hormones Market Growth in 2025: The Role of Rising Demand For Hormone Biosimilars Fueled By Prevalence Of Hormonal Deficiencies

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Biosimilar Hormones Market Size Growth Forecast: What to Expect by 2025?
The market size for biosimilar hormones has seen a massive growth recently. Expected to rise from $3.9 billion in 2024, it is estimated to reach $4.98 billion in 2025, yielding a compound annual growth rate (CAGR) of 27.5%. This growth during the historic period is due to factors such as an increase in chronic diseases, a growing elderly population, heightened awareness about biosimilar hormones, and wider access to healthcare facilities.

How Will the Biosimilar Hormones Market Size Evolve and Grow by 2029?
The market size of biosimilar hormones is anticipated to experience a significant surge in the forthcoming years, reaching a value of $11.77 billion in 2029, with a CAGR of 24.0%. The expansion anticipated in the forecast period is linked to factors such as increased hormone targets, greater acceptance by patients, advancements in manufacturing, support from the government, a surge in clinical trial data, and wider healthcare access. The primary trends expected during the forecast period comprise of personalized hormone replacement, new product introductions, pricing and accessibility, and emphasis on patient-centric care.

View the full report here:
https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report

What Drivers Are Propelling the Growth of Biosimilar Hormones Market Forward?
The hormone biosimilar market is positively impacted by the widespread deficiencies in growth and metabolic hormones. Over the years, as therapies for hormone-related conditions have advanced, the increased prevalence of hormone deficiencies has shown raised demand in the hormone biosimilar market. A UK-based, peer-reviewed medical trade journal called the British Medical Journal, stated in January 2022, that the incidence of GH deficiency (GHD) in children is estimated to be between 1 in 3500 and 1 in 10000 worldwide. Similarly, a Medscape report from June 2022 indicated a projected diagnosis of growth hormone (GH) deficiency in about 6,000 adults in the USA. It is this escalating requirement for treating patients with prevailing hormonal deficiencies that spurs the expansion of the biosimilar hormones market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3432&type=smp

Which Emerging Trends Are Transforming the Biosimilar Hormones Market in 2025?
The major players in the biosimilar hormones market are implementing several tactical strategies such as unveiling new products in unexplored regions to allow a wider population access to the drug. There is a concentrated effort by these companies to increase sales and reap maximum profits by introducing their products across diverse geographical locations. For instance, Alvotech Holdings S.A., a biopharmaceutical company from Luxembourg that specializes in the production of biosimilar medicines, announced a partnership with Fuji Pharma Co. Ltd., a pharmaceutical firm based in Japan, in February 2022. The purpose of this partnership is to develop biosimilar drug candidates in Japan. This strategic alliance intends to add fresh components into their corporate collaboration for the formulation and promotion of biosimilar medicines within the Japanese market.

What Are the Key Segments in the Biosimilar Hormones Market?
The biosimilar hormones market covered in this report is segmented -

1) By Type: Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars, Other Types
2) By Application: Research & Biotechnology, Diagnostics, Biocatalysts, Therapeutics, Other Applications
3) By Distribution Channel: Hospital And Retail Pharmacy, Online Pharmacy/pharmacy, Specialty Clinics

Subsegments:
1) By Teriparatide Biosimilars: Osteoporosis Treatment, Bone Health Maintenance
2) By Follitropin Alfa Biosimilars: Infertility Treatment, Assisted Reproductive Technology (ART)
3) By Insulin Biosimilars: Type 1 Diabetes Management, Type 2 Diabetes Management
4) By Somatropin Biosimilars: Growth Hormone Deficiency Treatment, Pediatric Growth Disorders
5) By Other Types: Thyroid Hormones, Corticosteroids

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=3432&type=smp

Who Are the Key Players Shaping the Biosimilar Hormones Market's Competitive Landscape?
Major companies operating in the biosimilar hormones market include Teva Pharmaceutical Industries Ltd., Gedeon Richter Plc., Intas Pharmaceuticals Ltd., Biocon Limited, Mylan, Sanofi, Sandoz Group AG, LG Life Sciences, Ferring Pharmaceuticals, GC Pharma, Pfizer Inc., Dr. Reddy's Laboratories, Amgen Inc., Eli Lilly and Company, Celltrion Inc., Samsungbioepis Co.Ltd, Merck & Co., Biogen Inc., Boehringer Ingelheim, Alvotech, BioXpress Therapeutics, Cipla Limited, Lupin Ltd., Stada Arzneimittel AG, Torrent Pharmaceuticals, Zydus Cadila, Accord Healthcare, Hetero Drugs, Wockhardt

What Geographic Markets Are Powering Growth in the Biosimilar Hormones Market?
The countries covered in the biosimilar hormones market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3432

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.